[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.74.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 5, 1994

Screening

Author Affiliations

Medical University of South Carolina Charleston

 

Hiroshi Naruse and Harvey L. Levy, editors-in-chief, quarterly, Dfl 358 (approx US $199), Amsterdam, the Netherlands, Elsevier Science Publishers, 1992-.

JAMA. 1994;272(13):1078-1079. doi:10.1001/jama.1994.03520130120048
Abstract

What are inborn errors of metabolism, and can newborn infants with these disorders be identified and treated with a favorable outcome? Only three decades ago these were common questions asked by the medical community. Today the basic answers are vaguely familiar even to the layperson.

Screening newborn infants and identifying those with inherited metabolic disorders require a team approach by physician and nonphysician scientists, skilled technologists, and public health workers—a process constituting "laboratory medicine on a mass scale in the public area."1 Newborn screening routinely identifies infants with metabolic disturbances such as phenylketonuria and congenital hypothyroidism. By detecting rare disorders early enough, their associated long-term complications, especially neurological deficits, can be reduced. If affected infants are identified within the first few weeks of life, their quality of life can be dramatically improved by recommended therapeutic interventions. Earlier detection of a larger number of genetic and nongenetic congenital disorders is

First Page Preview View Large
First page PDF preview
First page PDF preview
×